Abstract Till date, no breakthrough for systemic therapy of recurrent meningiomas has been achieved. The multitude of optional drugs shows that none of them so far could become a standard of care. On the other hand, although the disease is rare, each neurooncological centre has some patients with unmet treatment needs. Cohort studies should be able to answer the question whether meningiomas occur more rarely or do not become symptomatic in individuals undergoing treatment with statins, glitazones, or calcium channel blockers. If found effective, such drugs would be suitable as first line treatment in patients with grade I recurrent meningiomas, because for these indications most probably the long treatment periods appear necessary. For patients who recur with such drugs, targeted therapies could represent further treatment options, whereas cytotoxic drugs with severe side effects such as trabectedin could perhaps be investigated for recurrent malignant meningiomas after all other options.
Introduction
Most of the resectable meningiomas can be cured by surgery. However, a fraction of meningiomas WHO grade I recurs after surgery, as do atypical and malignant meningiomas. Most of them respond to radiation. However, rarely, meningiomas exhaust all local therapies [1] . Those patients have usually undergone several neurosurgical procedures and repeated courses of radiotherapy and/or radiosurgery when they are finally presented to the medical oncologist. These patients are heavily symptomatic, present with neurological deficits and most of them require anti-epileptic treatment to suppress meningioma related seizures. Moreover, in contrast to patients with WHO grade I meningiomas whose lifespan is usually not abridged, survival in patients with atypical meningiomas is shortened to 11.9 years and to 3.3 years in patients after the diagnosis of anaplastic meningioma [2] .
Treatment
There is no established or approved systemic treatment for patients with recurrent progressive, atypical, or malignant meningiomas after exhaustion of local treatments. Unlike gliomas, the meningiomas are not situated "behind" the blood brain barrier and circulating drugs should be able to penetrate into meningiomas. However, the increased intratumoral pressure could be high enough to preclude the penetration of drugs from the blood stream, especially in meningiomas causing large rims of vasogenic edema.
Most of the published experience relies on small (often retrospective) series or case reports.
Hormones

Antiprogesterones
The majority of benign meningiomas express progesterone receptors. Therefore, progesterone antagonists have been investigated in recurrent meningiomas. But progressive meningiomas tend to lose the expression of progesterone receptor and atypical meningiomas definitely lack it. This explains why progesterone antagonists were not successful in the treatment of recurrent and progressive meningiomas [3] .
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of treatment with long-acting somatostatin analogs in 16 patients with recurrent and atypical meningiomas. They observed 5 partial responses, 5 stabilisations, and progressive disease in 6 patients. PFS-6 was 44 %. The expression of somatostatin receptors on the meningioma can be visualized with a 111-Indium octreotide scan [4] .
An undeniable advantage of this treatment is that it requires only a monthly intramuscular injection; an important disadvantage is that this single injection might cause painful gastrointestinal cramps in patients with gallstones that might never have been symptomatic before. Ultrasound for the detection of gall stones should be mandatory before starting somatostatin injections. In a recent series of 12 patients treated with octreotide injections three times daily, Johnson et al. observed a median time to progression of only 4 months [5] .
Cytotoxic drugs
Historically, hydroxyurea, an ancient oral alkylating drug has most often been used. There are some series with hydroxyurea compiled in Table 1 . Generally, the drug was used at half of the dose used for treating chronic myelocytic leukemia and was well tolerated, but only moderately effective-if at all.
Anthracyclines
More toxic regimens used anthracyclines, either alone or in combinations [6] . The responses obtained are also mainly disease stabilizations, with a higher burden of side effects.
CPT11
Gupta et al. reported that irinotecan was active against meningioma cell lines and primo cell cultures and also in animal models [7] . Chamberlain et al. started a salvage study with 350 mg/m 2 irinotecan every 3 weeks in 16 patients with recurrent meningioma. Thirteen patients (81 %) demonstrated stable disease but disease progressed after 2 cycles of CPT-11. The survival ranged from 4 to 13 months, in median 7.5 months. This trial was stopped prematurely because of lack of efficacy [7, 8] .
Trabectedin
We have administered trabectedin-a novel marine cytostatic drug approved for the use in soft tissue sarcomas and ovarian cancer-to a patient with highly symptomatic, recurrent meningioma refractory to radiation and several targeted therapies. There was an unexpected rapid clinical response, as this patient recovered within one day from aphasia. Trabectedin showed high activity against primo cell cultures of atypical and malignant meningiomas (manuscript submitted).
Others
Dose dense temozolomide has been found ineffective in a series of 16 patients with recurrent, previously irradiated meningiomas [9] . 
Targeted therapies
Due to the lack of efficacy of treatment strategies against recurrent, progressive, atypical, and malignant meningiomas, targeted therapies interfering with the pathways found mutated or overexpressed in the progressive meningiomas were investigated as fast as they became available. Formal prospective studies are rare; the actual state appears more like a hypothesis finding phase, hopefully preceding a phase with intense study activity.
Imatinib
It has been known for long time that meningiomas express platelet derived growth factor beta and that meningioma proliferation is stimulated by autocrine growth stimulation loops [13] [14] [15] [16] . In a phase II conducted by the North American Brain Tumor Consortium, 23 heavily pretreated patients (13 benign, 5 atypical, and 5 malignant meningiomas) were treated with 600-800 mg Imatinib per day. The study was closed prematurely due to low accrual, but median PFS reached only two months [17] . Reardon et al. treated 21 patients with hydroxyurea and imatinib, PFS-6 was 61 %. Our own experience on 9 patients is favorable (manuscript submitted), but we observed a severe, happily reversible, hepatic toxicity in one patient [17, 18] .
Gefitinib and erlotinib
As many meningiomas show overexpression of the epidermal growth factor, an exploratory trial was conducted in 25 patients with recurrent meningiomas (8 meningiomas WHO grade I, 9 atypical, and 8 malignant) using either gefitinib (500 mg/day) or erlotinib (150 mg/day). For benign tumors, PFS-6 was 25 %. For atypical and malignant meningiomas, PFS-6 was 29 %. Stable disease maintained by 32 % of patients. Nevertheless, the authors considered the treatment with epithelial growth factor antagonists as ineffective [19] .
Avastin
Recurrent meningiomas show increasing microvascular density and VEGF expression, suggesting a potential role of neoangiogenesis in the proliferation of meningiomas (Hassler, unpublished results [20] [21] [22] ). Drugs targeting VEGF-R have been used in recurrent meningiomas, mainly in case studies [20, 23] . In our own experience, bevacizumab achieves a rapid clinical improvement in patients with significant peritumoral edema.
Multikinase inhibitors
Several other inhibitors of PDGF are undergoing evaluation, including sunitinib, MLN518, dasatinib, AMN 107, pazopanib, sorafenib, CP673451, and CHIR 265; sunitinib and pazopanib [24] .
Other drugs
Karlsson et al. [25] described the presence of estramustine-binding protein on the cell membranes of six meningiomas in concentrations similar to prostate cancer cells, which suggests that the potential of treating recurrent meningiomas with estramustine could be investigated. Calcium channel antagonists such as nifedipine, diltiazem, and verapamil can block calcium mediated growth signals to PDGFR and other growth factors expressed by meningiomas. It could be shown that meningiomas in patients treated with calcium channel blockers were generally smaller and less vascularised than in other patients [26] .
Park et al. [27, 28] report that the resin of the incense tree, Acetyl-11-keto-beta-boswellic acid (AKBA) has been identified as inhibitor of topoisomerase I and II. AKBA showed a potent cytotoxic activity on primo cell cultures of 11 meningiomas in the concentration of 2-8 µM/L.
A different approach was tested by Gehring et al. on two cell lines from benign meningiomas [29] [30] [31] [32] . Statins inhibit the rate limiting step of hepatic cholesterol synthesis. Cholesterol is an essential component of cell membranes thus indispensable for dividing normal or tumor cells. Moreover, statins are known to regulate Ras and Rho, inhibiting the activation of the mitogen-activated protein kinase pathway (MAPK). Statins have shown considerable apoptosis induction on glioma cell lines with concentrations similar to higher therapeutic levels given against hyperlipidemia [30] [31] [32] . Glitazones are drugs used for decreasing insulin resistance in diabetes mellitus type 2, but they were also shown to induce cell cycle arrest, differentiation and/or apoptosis in tumor cells in vitro by induction of reactive oxygen species. Gehring et al. used both drugs alone and in combination and were able to demonstrate a synergistic proapototic effect in the meningioma cell lines.
Summary
To date, no breakthrough for systemic therapy of recurrent meningiomas has been achieved. The multitude of optional drugs shows that none of them so far could become a standard of care. On the other hand, although the disease is rare, each neurooncological centre has some patients with unmet treatment needs.
Cohort studies should be able to answer the question whether meningiomas occur more rarely or do not become symptomatic in individuals under treatment with statins, glitazones, or calcium channel blockers. If found effective, such drugs would be suitable as first line treatment in patients with grade I recurrent meningiomas, as for these indications most probably long treatment periods appear necessary. For patients who recur with such drugs, targeted therapies could represent further treatment options, whereas cytotoxic drugs with severe side effects as trabectedin could perhaps be investigated for recurrent malignant meningiomas after all other options.
